Prevalence of Cardiovascular Risk Factors in Male and Female Patients with Primary Hyperparathyroidism

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2011 Jul 14

PMID 21750400

Citations 18

Authors

D Han

S Trooskin

X Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the prevalence of cardiovascular risk factors in patients with primary hyperparathyroidism (PHPT) and to determine if they are gender specific.

Methods: This was a retrospective case control study. Three hundred and sixty-three men and women with PHPT and 363 age-, sex-, and body mass index (BMI)-matched controls with benign goiter were included in the study. We documented each patient's laboratory results along with the presence of any cardiovascular risk factors. Intra-operatively, the resected parathyroid adenomas were weighed and recorded. The data are expressed as the number of patients in each category and percentage of total patients in that group and the mean±SD.

Results: The prevalence of obesity, hypertension, hyperlipidemia, Type 2 diabetes, and coronary artery disease (CAD) is higher in PHPT patients compared to the general New Jersey population and age-, sex-, and BMI-matched goiter patients. Male PHPT patients tended to be more obese and were found to have heavier parathyroid adenomas compared to female patients (p<0.05). Additionally, a higher percentage of male PHPT patients were found to have higher rates of CAD (11.5%) and Type 2 diabetes (23.0%) compared to female patients (5.80% and 10.9%, respectively, p<0.05).

Conclusions: There is a higher prevalence of metabolic disorders and CAD in PHPT patients. Male PHPT patients had larger parathyroid adenomas at the time of surgery and had a higher prevalence of obesity, Type 2 diabetes and CAD compared to female PHPT patients.

Citing Articles

Alterations in serum levels of calcium, vitamin D, phosphorus, and parathyroid hormone in patients with clinically confirmed familial hypercholesterolemia: a cross-sectional study.

Heshmat-Ghahdarijani K, Vaseghi G, Hajian S, Taheri M, Haghjooy-Javanmard S, Sarrafzadegan N Ann Med Surg (Lond). 2024; 86(11):6502-6506.

PMID: 39525785 PMC: 11543173. DOI: 10.1097/MS9.0000000000002558.

[Gender medicine: endocrine and neuroendocrine diseases : Implications for surgery and perioperative management].

Butz F, Muller-Debus C, Mogl M Chirurgie (Heidelb). 2024; 95(9):736-741.

PMID: 39102037 DOI: 10.1007/s00104-024-02140-8.

Cardiovascular and metabolic status in patients with primary hyperparathyroidism: a single-center experience.

Dobreva E, Gorbacheva A, Bibik E, Eremkina A, Elfimova A, Salimkhanov R Front Endocrinol (Lausanne). 2023; 14:1266728.

PMID: 37842310 PMC: 10570793. DOI: 10.3389/fendo.2023.1266728.

Investigating the risk of metabolic and cardiovascular comorbidities among patients with parathyroid cancer: a nationwide representative cohort study in Taiwan.

Tsai M, Hsu M, Hsu H, Yeh T, Chiang C, Lee W BMC Med. 2023; 21(1):249.

PMID: 37424030 PMC: 10332013. DOI: 10.1186/s12916-023-02946-z.

Stable Incidence and Increasing Prevalence of Primary Hyperparathyroidism in a Population-based Study in Scotland.

Soto-Pedre E, Newey P, Leese G J Clin Endocrinol Metab. 2023; 108(10):e1117-e1124.

PMID: 37022975 PMC: 10505547. DOI: 10.1210/clinem/dgad201.

References

Ayturk S, Gursoy A, Tutuncu N, Ertugrul D, Demirag N . Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2006; 91(11):4260-3. DOI: 10.1210/jc.2005-2825. View

Wermers R, Khosla S, Atkinson E, Grant C, Hodgson S, OFallon W . Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med. 1998; 104(2):115-22. DOI: 10.1016/s0002-9343(97)00270-2. View

Nilsson I, Yin L, Lundgren E, Rastad J, Ekbom A . Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res. 2002; 17 Suppl 2:N68-74. View

Shaw J, Purdie D, Neil H, Levy J, Turner R . The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus. Diabetologia. 1999; 42(1):24-7. DOI: 10.1007/s001250051107. View

Marcus R . The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res. 2002; 17 Suppl 2:N146-9. View

Li X, Qin L, Bergenstock M, Bevelock L, Novack D, Partridge N . Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem. 2007; 282(45):33098-106. DOI: 10.1074/jbc.M611781200. View

Rao D, Wilson R, Kleerekoper M, Parfitt A . Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 1988; 67(6):1294-8. DOI: 10.1210/jcem-67-6-1294. View

Silverberg S, Shane E, JACOBS T, Siris E, Bilezikian J . A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999; 341(17):1249-55. DOI: 10.1056/NEJM199910213411701. View

Bolland M, Grey A, Gamble G, Reid I . Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2004; 90(3):1525-30. DOI: 10.1210/jc.2004-1891. View

10.

Guo C, THOMAS W, Assiri A, Eastell R . Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81(10):3487-91. DOI: 10.1210/jcem.81.10.8855790. View

11.

Kamycheva E, Sundsfjord J, Jorde R . Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol. 2004; 151(2):167-72. DOI: 10.1530/eje.0.1510167. View

12.

SCHOLZ D, PURNELL D . Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc. 1981; 56(8):473-8. View

13.

Vestergaard P, Mosekilde L . Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003; 327(7414):530-4. PMC: 192894. DOI: 10.1136/bmj.327.7414.530. View

14.

Wermers R, Khosla S, Atkinson E, Achenbach S, Oberg A, Grant C . Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2005; 21(1):171-7. DOI: 10.1359/JBMR.050910. View

15.

Xu K, Borders T . Gender, health, and physician visits among adults in the United States. Am J Public Health. 2003; 93(7):1076-9. PMC: 1447909. DOI: 10.2105/ajph.93.7.1076. View

16.

Bollerslev J, Jansson S, Mollerup C, Nordenstrom J, Lundgren E, Torring O . Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007; 92(5):1687-92. DOI: 10.1210/jc.2006-1836. View

17.

Vestergaard P, Mollerup C, Frokjaer V, Christiansen P, Blichert-Toft M, Mosekilde L . Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003; 27(2):216-22. DOI: 10.1007/s00268-002-6541-z. View

18.

Khan A, Bilezikian J, Potts Jr J . The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab. 2009; 94(2):333-4. DOI: 10.1210/jc.2008-1757. View

19.

Siilin H, Rastad J, Ljunggren O, Lundgren E . Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab. 2007; 93(1):47-53. DOI: 10.1210/jc.2007-0600. View

20.

Adam M, Untch B, Danko M, Stinnett S, Dixit D, Koh J . Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab. 2010; 95(11):4917-24. PMC: 3205600. DOI: 10.1210/jc.2010-0666. View